TN2010000155A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number: TN2010000155A1
Authority: TN; Tunisia
Prior art keywords: organic compounds; modulator; parkinson; progression; disease
Prior art date: 2007-10-12

Application number

TN2010000155A

Other languages

English (en)

Inventor

Daniel Umbricht

Mancilla Baltazar Gomez

Fabrizio Gasparini

Paolo Therese Di

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-10-12

Filing date

2010-04-12

Publication date

2011-11-11

2010-04-12 Application filed by Novartis Ag filed Critical Novartis Ag

2011-11-11 Publication of TN2010000155A1 publication Critical patent/TN2010000155A1/fr

Links

150000002894 organic compounds Chemical class 0.000 title 1
102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 1
108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 1
102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)

TN2010000155A 2007-10-12 2010-04-12 Organic compounds TN2010000155A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US97948607P	2007-10-12	2007-10-12
US5033308P	2008-05-05	2008-05-05
PCT/EP2008/063544 WO2009047296A2 (fr)	2007-10-12	2008-10-09	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2010000155A1 true TN2010000155A1 (en)	2011-11-11

Family

ID=40348021

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2010000155A TN2010000155A1 (en)	2007-10-12	2010-04-12	Organic compounds

Country Status (19)

Country	Link
US (2)	US20100249136A1 (fr)
EP (1)	EP2211859B1 (fr)
JP (2)	JP5743545B2 (fr)
KR (1)	KR101572280B1 (fr)
CN (1)	CN101854935A (fr)
AU (1)	AU2008309621A1 (fr)
BR (1)	BRPI0818560A2 (fr)
CA (1)	CA2701853A1 (fr)
CL (1)	CL2008003006A1 (fr)
IL (1)	IL204954A0 (fr)
MA (1)	MA31798B1 (fr)
MX (1)	MX2010003913A (fr)
NZ (1)	NZ584856A (fr)
RU (1)	RU2508107C2 (fr)
SG (1)	SG185293A1 (fr)
TN (1)	TN2010000155A1 (fr)
TW (1)	TW200924745A (fr)
WO (1)	WO2009047296A2 (fr)
ZA (1)	ZA201002423B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2010014222A (es) *	2008-06-30	2011-03-29	Novartis Ag Star	Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
MX2011001664A (es) *	2008-08-12	2011-03-25	Novartis Ag	Procesos para la preparacion del metil-ester del acido 4-oxo-octahidro-indol-1-carbociclico y derivados del mismo.
CA2774373A1 (fr) *	2009-09-17	2011-03-24	Vanderbilt University	Analogues d'heteroarylamide substitue en tant que modulateurs allosteriques negatifs de mglur5, et leurs procedes de preparation et d'utilisation
JP2014515008A (ja) *	2011-03-03	2014-06-26	ヴァンダービルトユニバーシティー	Ｍｇｌｕｒ５の負のアロステリック調節剤としての６−アルキル−ｎ−（ピリジン−２−イル）−４−アリールオキシピコリンアミド類似体ならびにそれを作製および使用する方法
US20140228398A1 (en)	2011-03-18	2014-08-14	Novartis Ag	COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
GB201204962D0 (en)	2012-03-21	2012-05-02	Addex Pharmaceuticals Sa	Pharmaceutical combination products for parkinsons disease
EP3071568A1 (fr)	2013-11-19	2016-09-28	Vanderbilt University	Composés imidazopyridine et triazolopyridine substitués utilisés comme modulateurs allostériques négatifs de mglur
US9533982B2 (en)	2014-03-20	2017-01-03	Vanderbilt University	Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en)	2014-10-03	2017-01-24	Vanderbilt University	Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
KR101749675B1 (ko) *	2015-07-20	2017-06-26	동국대학교 산학협력단	멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6379666B1 (en) *	1999-02-24	2002-04-30	Edward L. Tobinick	TNF inhibitors for the treatment of neurological, retinal and muscular disorders
CN1361768A (zh) *	1999-06-02	2002-07-31	Nps药物有限公司	代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
GB0128996D0 (en) *	2001-12-04	2002-01-23	Novartis Ag	Organic compounds
EP1458708B1 (fr) *	2001-12-18	2007-09-26	Merck & Co., Inc.	Modulateurs triazole substitues par heteroaryle du recepteur metabotropique 5 du glutamate
EP1539749A4 (fr) *	2002-09-13	2007-06-13	Merck & Co Inc	Modulateurs du recepteur glutamate metabotropique 5 (mglur5) de phenyle substitues par un fragment heterobicyclo fusionne
EP1596808A4 (fr) *	2003-02-07	2007-04-04	Yissum Res Dev Co	Derives d'amide l-dopa et utilisations de ceux-ci
WO2005030128A2 (fr) *	2003-09-23	2005-04-07	Merck & Co., Inc.	Modulateurs pyrazole de recepteurs de glutamate metabotropiques
JP2007524682A (ja) *	2004-02-12	2007-08-30	メルク　エンド　カムパニー　インコーポレーテッド	代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド
US7414060B2 (en) *	2005-03-04	2008-08-19	Hoffmann-La Roche Inc.	Pyridine-2-carboxyamide derivatives
GB0508318D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
GB0508319D0 (en) *	2005-04-25	2005-06-01	Novartis Ag	Organic compounds
TW200801005A (en) *	2005-08-15	2008-01-01	Astrazeneca Ab	Acetylenic piperazines as metabotropic glutamate receptor antagonists
AR058554A1 (es) *	2005-12-20	2008-02-13	Novartis Ag	Compuestos heterociclicos nitrogenados de 6 miembros sustituidos, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades mediadas por mglur5.
EP2272509A1 (fr) *	2006-09-11	2011-01-12	Novartis AG	Nouvelles utilisations des récepteurs du glutamate métabotropique
MX2010014222A (es) *	2008-06-30	2011-03-29	Novartis Ag Star	Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.

2008
- 2008-10-09 US US12/682,624 patent/US20100249136A1/en not_active Abandoned
- 2008-10-09 MX MX2010003913A patent/MX2010003913A/es active IP Right Grant
- 2008-10-09 CA CA2701853A patent/CA2701853A1/fr not_active Abandoned
- 2008-10-09 WO PCT/EP2008/063544 patent/WO2009047296A2/fr not_active Ceased
- 2008-10-09 JP JP2010528396A patent/JP5743545B2/ja not_active Expired - Fee Related
- 2008-10-09 NZ NZ584856A patent/NZ584856A/xx not_active IP Right Cessation
- 2008-10-09 EP EP08805185.9A patent/EP2211859B1/fr not_active Not-in-force
- 2008-10-09 RU RU2010118454/15A patent/RU2508107C2/ru not_active IP Right Cessation
- 2008-10-09 SG SG2012075677A patent/SG185293A1/en unknown
- 2008-10-09 CN CN200880110746A patent/CN101854935A/zh active Pending
- 2008-10-09 AU AU2008309621A patent/AU2008309621A1/en not_active Abandoned
- 2008-10-09 KR KR1020107010331A patent/KR101572280B1/ko not_active Expired - Fee Related
- 2008-10-09 BR BRPI0818560A patent/BRPI0818560A2/pt not_active IP Right Cessation
- 2008-10-09 TW TW097139070A patent/TW200924745A/zh unknown
- 2008-10-10 CL CL2008003006A patent/CL2008003006A1/es unknown
2010
- 2010-04-07 ZA ZA2010/02423A patent/ZA201002423B/en unknown
- 2010-04-08 IL IL204954A patent/IL204954A0/en unknown
- 2010-04-12 TN TN2010000155A patent/TN2010000155A1/fr unknown
- 2010-04-30 MA MA32804A patent/MA31798B1/fr unknown
2014
- 2014-08-29 JP JP2014175983A patent/JP2014240425A/ja active Pending
2015
- 2015-06-11 US US14/736,901 patent/US20150272929A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2011500529A (ja)	2011-01-06
RU2010118454A (ru)	2011-11-20
JP5743545B2 (ja)	2015-07-01
WO2009047296A2 (fr)	2009-04-16
MX2010003913A (es)	2010-04-27
JP2014240425A (ja)	2014-12-25
TW200924745A (en)	2009-06-16
CA2701853A1 (fr)	2009-04-16
IL204954A0 (en)	2010-11-30
US20100249136A1 (en)	2010-09-30
ZA201002423B (en)	2010-12-29
KR20100088136A (ko)	2010-08-06
EP2211859A2 (fr)	2010-08-04
CL2008003006A1 (es)	2009-05-08
AU2008309621A1 (en)	2009-04-16
BRPI0818560A2 (pt)	2019-09-24
SG185293A1 (en)	2012-11-29
WO2009047296A3 (fr)	2009-08-20
KR101572280B1 (ko)	2015-11-26
NZ584856A (en)	2012-12-21
CN101854935A (zh)	2010-10-06
MA31798B1 (fr)	2010-10-01
RU2508107C2 (ru)	2014-02-27
EP2211859B1 (fr)	2016-01-06
US20150272929A1 (en)	2015-10-01

Publication	Publication Date	Title
MX2010003913A (es)	2010-04-27	Moduladores de los receptores de glutamato metabotropicos para el tratamiento de enfermedades de parkinson.
MX2009006536A (es)	2009-06-26	Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
MX2009008347A (es)	2009-10-19	Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
IL195256A0 (en)	2009-08-03	Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2008124660A3 (fr)	2008-11-27	Procédés et compositions pour le traitement du cancer
PH12015500550A1 (en)	2016-06-13	Anti-notch1 nrr antibodies and methods using same
TN2010000122A1 (en)	2011-09-26	Compounds and compositions as modulators of gpr119 activity
MX2009012625A (es)	2009-12-07	Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
PL2134704T3 (pl)	2011-03-31	Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
WO2006119295A3 (fr)	2007-03-15	Compositions et methodes de traitement de maladies neurodegeneratives
MX2009013082A (es)	2010-01-15	Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
TNSN08400A1 (en)	2010-04-14	Organic compounds and their uses
MX2007009356A (es)	2007-12-07	Compuestos y composiciones como moduladores de ppar.
MX2009002684A (es)	2009-06-05	Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico.
TNSN08496A1 (en)	2010-04-14	Aminothiazoles and their uses
MX2010000956A (es)	2010-03-01	Derivados de isoftalamida que inhiben actividad de beta-secretasa.
MX2009009693A (es)	2009-10-07	Metodos para activar irs-1 y akt.
NL1030418A1 (nl)	2006-05-16	Azabenzoxazolen voor de behandeling van CZS-stoornissen.
MX2009013214A (es)	2010-01-15	Macrociclos y sus usos.
MX2010004463A (es)	2010-05-03	Compuestos de indolina.
WO2009051661A3 (fr)	2009-07-16	Analogues-oxy-alkylamino aryle substitués et utilisations de ceux-ci
WO2008085927A3 (fr)	2008-09-18	Procédés, compositions et kits destinés au traitement de la douleur
WO2008103431A3 (fr)	2009-06-25	Liposomes adni
WO2008008841A3 (fr)	2008-05-29	Utilisation de dérivés de benzimidazoles pour le traitement et/ou la prévention de désordres autoimmunitaires
NL1032552C2 (nl)	2007-09-25	Imidazoolverbindingen voor de behandeling van neurologische stoornissen.